Yurt Kilcar A.Biber Muftuler F.Z.Enginar H.Tekin V.Medine E.I.Unak P.2019-10-272019-10-2720140236-57310236-5731https://doi.org/10.1007/s10967-014-3175-1https://hdl.handle.net/11454/26237Recently, the development of novel brain imaging agents has aroused much interest thanks to limited number of brain cancer or diseases diagnosis agents. It is aimed to synthesize a novel brain imaging agent including a promise for further studies on AD diagnosis potential and investigate its bioaffinity with biodistribution studies on healthy Balb/c mice. A novel radiolabeled agent was synthesized and characterized. Quality control of 99mTc-BH was performed utilizing solvent extraction and chromatographic (Radio TLC and Radio HPLC) methods. Bioaffinity of the 99mTc-BH was investigated on male Balb/c mice at various time points (5, 30, 60, 120 min post-injection). Paper electrophoresis showed that 99mTc-BH has a neutral structure. Radiochemical purity of 99mTc-BH was over 95 % with appropriate stability for imaging period. Selected brain regions have uptakes over 4 % ID/g following intravenous injection. Hippocampus has uptake approximately 10 % ID/g. 99mTc-BH has shown brain uptake, so it may prove to be valuable for brain imaging as a novel technetium-labeled agent. Further investigations with AD animal model are our on going effort to show that this agent has AD diagnosis potential. © 2014, Akadémiai Kiadó, Budapest, Hungary.en10.1007/s10967-014-3175-1info:eu-repo/semantics/closedAccess99mTcBioquinBrain imagingHMPAOArticle3021563573Q2